The human papillomavirus vaccination has reportedly reduced the prevalence of HPV by 56 percent in the female adolescent population. A study recently published in the Journal of Infectious Diseases revealed that the frequency of the infection among adolescent females between the ages of 14 to 19 has significantly decreased.
According to the Centers for Disease Control and Prevention, HPV, has more than 40 different types and variations, and it is one of the most common sexually transmitted diseases in the U.S. It can lead to several different types of cancers, predominantly cervical cancer. The infection can affect both females and males, and it is usually found in the genital area, mouth or throat. HPV is transmitted through vaginal, oral, anal sex or any other genital contact.
The HPV vaccine was created in 2006 and was designed as a three-shot regimen given over a period of six months to young teens, ideally before they became sexually active.
Before the vaccine was introduced, around 12 percent of females between 14 and 19 years old tested positive for HPV. Within three years of the vaccination entering the market, only 5 percent of the same population were HPV-positive.
Thomas Frieden, director of the CDC, was very impressed by the vaccination results.
"It is possible to protect the next generation from cancer, and we need to do it," Frieden said.
Frieden also stated that in America, only one-third of females ages 13 to 17 have received all three shots. However, in various countries in Europe, and in Australia and Rwanda, there is a significantly higher percentage of females that have received the full set, compared to America.
Medical News Today reported that the price for HPV vaccines has decreased, which makes them more affordable for a number of girls in underdeveloped countries than they were before.
CDC recommends other ways to prevent HPV, such as using a condom correctly and limiting the number of partners that one is sexually active with.